Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

May 21, 2020 by Alan Khadavi

High dose Xolair for chronic hives

High dose Xolair may be a treatment option for patients with chronic hives who fail the standard treatment dose of 300mg monthly. Xolair (omalizumab) is a monoclonal anti-IgE antibody for patients who have chronic spontaneous urticaria who fail the 4 fold standard dosing of antihistamines.

Stepwise approach to Chronic Urticaria (Chronic Hives)

A recent study published in the Journal of Allergy and Clinical Immunology: In Practice, increased the dose of Xolair in patients who failed to respond to the standard Xolair 300mg dosage.

All patients were initially treated with Xolair 300mg for 4 weeks. Patients who failed to respond after 5 injections, updosing was offered.

Response of hives after treatment with Xolair

The high dose Xolair offered was 450 mg or 600 mg every 4 weeks.  If treatment response was still insufficient after 3 doses of 600mg of Xolair, treatment interval could be shortened to 2 weeks. Xolair was discontinued in cases in which 2 consecutive doses of 600 mg at 2-week interval yielded insufficient response.

A total of 166 patients were treated with Xolair. Higher doses of Xolair were introduced after an average of 8 administrations of a standard dose of 300mg every 4 weeks. 61% of the patients who received the higher dose of Xolair showed an improved treatment response, about half of them showed a complete response and the other half of them showed a partial response. Approximately 40% of them did not improve from updosing.

We discussed in another blog post, other alternatives to treatment failures in chronic urticaria with Xolair.

Severe Hives Treatment (Xolair and Cyclosporine)

Although high dose Xolair is generally used in patients with asthma based on their weight and IgE level, it is rarely used in chronic idiopathic urticaria.  Other smaller studies have showed comparable results, anywhere from 45%-83% of partial or complete response.

The most frequent side effects during high dose Xolair treatment were headache, fever like sensations and tiredness, which were not increased compared to standard treatment. Likewise, higher doses of Xolair are well tolerated in patients with asthma.

Can you taper your Xolair dosage for hives?

Filed Under: Blog, hives

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page